ACC latest: Lilly, Merck, Pfizer, Novartis and more unveil key data

Tracy Staton You missed the American College of Cardiology meeting. That's OK. The most newsworthy research coming out of the meeting is gathered right here, with almost every Big ...

Codiak piles on more venture cash, amassing $92M for exosome R&D

Damian Garde Startup Codiak BioSciences got off the ground in November with ambitious plans to turn exosomes into cancer therapies and venture commitments totaling more than $ 80 million. ...

Pfizer CEO: Allergan deal is ‘a lot more about growth’ than job cuts

Carly Helfand Anyone who's examined Pfizer's job-chopping track record knows the company has a tendency to wield the ax in the wake of a megamerger. But this time? Things will ...

#JPM16 Roundup: What you need to know on Pfizer, Sanofi and more

Carly Helfand SAN FRANCISCO–On Monday, we brought you the lowdown from the J.P. Morgan Healthcare Conference, with company presentations from pharma giants including Novartis ...

Juno buys into sequencing; Moderna cozies up to Big Pharma; and more from #JPM16

Damian Garde In the requisite flood of dealmaking that marks day one of San Francisco's annual J.P. Morgan Healthcare Conference, high-profile biotechs Juno Therapeutics and Moderna ...

Onslaught of new drugs will shake up MS, diabetes, cancer and more

Tracy Staton A bumper crop of FDA approvals in 2015 means an equal number of launches to keep an eye on in 2016. Last year, FiercePharmaMarketing brought you a list of 8 markets to ...

VCs: Venture funding grows, with more money for startups

John Carroll That IPO boom was just what the VC doctor ordered. Between high-priced buyout deals and new offerings, the venture funds got the exits they needed to look good to investors ...

Pfizer, Merck KGaA launch two more PhIII trials for avelumab

John Carroll The companies say that these two Phase III studies bring the late-stage program up to 6 studies, meeting their goal for 2015. FierceBiotech News

FDA rejects AstraZeneca’s diabetes combo and demands more data

Damian Garde The FDA wants to see more clinical trial data on AstraZeneca's new combination diabetes treatment, the company said, likely delaying a potential launch by more than ...

More grist for PCSK9 fight as Amgen sets up EU to pay about half as much as U.S.

Tracy Staton Last week, Amgen won its much-anticipated FDA approval for the PCSK9 cholesterol-fighter Repatha and promptly set a price of $ 14,100 per year. But even after pharmacy ...

Shire might dial up its $30B Baxalta offer, but not without more info

Alok Saboo Shire may consider upping its pitch for Baxalta, but first it needs more details on the financial future of its target. FierceBiotech News

With more consolidation on tap in generics, who’s next to buy and be bought?

Carly Helfand FiercePharma News
Page 1 of 812345...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS